UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June 18, 2007
--------------------------------------------
Date of Report
(Date of earliest event reported)
ZYMOGENETICS, INC.
(Exact Name of Registrant as Specified in Charter)
Washington 000-33489 91-1144498
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer
of Incorporation) Identification No.)
1201 Eastlake Avenue East, Seattle, Washington 98102-3702
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices, including Zip Code)
(206) 442-6600
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into Material Definitive Agreement.
On June 18, 2007, ZymoGenetics, Inc. entered into a multi-year, global license
and collaboration agreement with Bayer Schering Pharma A.G. and a multi-year
U.S. co-promotion agreement with a Bayer Schering affiliate, Bayer Healthcare
LLC, to help maximize the potential of ZymoGenetics' most advanced product
candidate, recombinant human thrombin (rThrombin). The agreements, among other
things, provide that Bayer Schering will commercialize rThrombin outside the
United States and will pay ZymoGenetics an upfront payment plus potential
milestone payments and royalties beginning upon approval of rThrombin in the
United States and Bayer Healthcare will co-promote certain ZymoGenetics'
rThrombin products in the United States for the first three years following
product launch and receive certain sales commissions and potential sales-based
milestone bonuses. The company's press release issued June 19, 2007 relating to
the agreements is attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) 99.1 Press Release dated June 19, 2007
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZYMOGENETICS, INC.
Dated: June 22, 2007 By /s/ James A. Johnson
---------------------------------
James A. Johnson
Senior Vice President,
Chief Financial Officer
Exhibit Index
99.1 Press Release issued June 19, 2007